Brighton Jones’s Monte Rosa Therapeutics GLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-9,746
Closed -$236K – 1442
2026
Q2
$236K Sell
9,746
-770
-7% -$14.5K ﹤0.01% 1174
2026
Q1
$173K Buy
+10,516
New +$201K ﹤0.01% 1104
2025
Q3
– Sell
-10,559
Closed -$47.6K – 1044
2025
Q2
$47.6K Buy
+10,559
New +$47.1K ﹤0.01% 907

Other funds holding GLUE

Brighton Jones's GLUE Position: Q3 2026 in Review

Brighton Jones sold out of Monte Rosa Therapeutics (GLUE) in Q3 2026, closing a stake of 9,746 shares — an estimated $236K sold.

Brighton Jones first reported a position in GLUE in Q2 2025 and held it in 3 quarters. The position peaked at $236K in Q2 2026. 142 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

  • Brighton Jones reported no remaining Monte Rosa Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Brighton Jones sold 9,746 Monte Rosa Therapeutics shares in Q3 2026, an estimated $236K.
  • Brighton Jones first reported a position in Monte Rosa Therapeutics in Q2 2025 and held it in 3 quarters.
  • Brighton Jones's Monte Rosa Therapeutics position peaked at $236K in Q2 2026.
  • 142 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Brighton Jones's 13F filing for Q3 2026, filed 3 Nov 2026.